Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEMETREXED FOR INJECTION vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pemetrexed is a folate analog metabolic inhibitor that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent de novo synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Malignant pleural mesothelioma in combination with cisplatin for unresectable or patients who are not candidates for curative surgery,Non-small cell lung cancer (NSCLC), first-line treatment in combination with cisplatin for nonsquamous histology,NSCLC maintenance therapy for nonsquamous histology after platinum-based therapy,NSCLC second-line treatment for nonsquamous histology
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin 75 mg/m² IV over 2 hours starting 30 minutes after pemetrexed completion. Administer folic acid 350-1000 µg po daily starting 7 days before first dose and continuing until 21 days after last dose, vitamin B12 1000 µg IM 7 days before first dose and every 3 cycles thereafter, and dexamethasone 4 mg po twice daily on day before, day of, and day after pemetrexed.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function (creatinine clearance ≥90 m L/min). In patients with impaired renal function (creatinine clearance 45-79 m L/min), the half-life may be prolonged to 4-5 hours.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Pemetrexed is minimally metabolized; it is primarily excreted unchanged in urine via active tubular secretion and glomerular filtration. No significant hepatic metabolism. Enzymes: not extensively metabolized by CYP450.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Approximately 70-90% of the administered dose is excreted unchanged in the urine within 24 hours. Renal elimination is the primary route, with negligible biliary or fecal excretion (<5%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 81-88% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
The volume of distribution at steady state is approximately 16.1 L/m² (or roughly 0.4 L/kg based on average body surface area). This low value suggests limited extravascular distribution, consistent with a hydrophilic drug.
4-6 L/kg; large Vd indicates extensive tissue distribution
Pemetrexed is administered only intravenously; oral bioavailability is not applicable (0% due to lack of oral formulation).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl ≥45 m L/min: No dose adjustment. Cr Cl <45 m L/min: Contraindicated; do not administer. For Cr Cl between 40-79 m L/min, consider dose reduction to 400 mg/m² if prior grade 3/4 toxicity. Monitor Cr Cl prior to each cycle.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: No recommended dose adjustment. Class C: No data; use with caution. Bilirubin >5 times ULN: Avoid use. AST/ALT >5 times ULN: Consider dose reduction to 400 mg/m² if severe transaminase elevation with bilirubin >3 times ULN.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Safety and efficacy not established in pediatric patients. No recommended dose.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No dose adjustment based on age alone. Monitor renal function (Cr Cl) closely; elderly more likely to have decreased Cr Cl and require dose reduction or discontinuation per renal adjustment criteria. Evaluate for increased risk of myelosuppression and fatigue.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Pemetrexed can cause severe myelosuppression, including severe neutropenia, anemia, and thrombocytopenia. Fatalities have been reported. Patients must have absolute neutrophil count (ANC) ≥1500 cells/mm³ and platelet count ≥100,000 cells/mm³ prior to initiation. Dose reduction or delay is required based on nadir counts.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Bone marrow suppression (dose-dependent); renal toxicity (requires adequate renal function, Cr Cl ≥45 m L/min); gastrointestinal toxicity (nausea, vomiting, mucositis); dermatologic reactions (rash, desquamation); radiation recall; requires folic acid and vitamin B12 supplementation to reduce toxicity; pregnancy category D; fetal harm; hypersensitivity reactions.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
History of severe hypersensitivity reaction to pemetrexed; Cr Cl <45 m L/min for patients with mesothelioma receiving cisplatin; concurrent yellow fever vaccine (live attenuated).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific dietary restrictions. However, vitamin B12 (from animal products) and folic acid (from leafy greens) are essential supplements. Avoid high-folate foods only if advised by physician (unlikely, as supplementation is required).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pemetrexed is teratogenic and embryotoxic in animal studies. In humans, it is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure carries high risk of major congenital malformations, spontaneous abortion, and fetal death. Second and third trimester exposure increases risk of intrauterine growth restriction, oligohydramnios, and fetal myelosuppression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
No data on pemetrexed excretion in human milk. Due to potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during treatment and for at least 1 week after last dose. M/P ratio not established.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No established dosing guidelines in pregnancy due to contraindication. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may reduce drug exposure, but dose adjustments are not recommended because of teratogenicity and lack of safety data. Treatment should be avoided or pregnancy terminated if exposure occurs.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Pemetrexed requires folic acid and vitamin B12 supplementation to reduce hematologic and gastrointestinal toxicity. Administer dexamethasone prophylaxis to prevent skin rash. Contraindicated in patients with creatinine clearance <45 m L/min. Avoid concurrent NSAIDs in patients with mild to moderate renal impairment (Cr Cl 45-79 m L/min) as they may increase pemetrexed toxicity.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take folic acid daily and vitamin B12 injections as prescribed to reduce side effects.,Report any skin rash, diarrhea, or mouth sores immediately.,Avoid aspirin and NSAIDs unless approved by your doctor, especially if you have kidney problems.,Stay hydrated and monitor for signs of infection (fever, chills).,Do not skip or stop your vitamin supplements even if you feel well.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide."
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
"Pemetrexed may increase the immunosuppressive activities of Fingolimod."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEMETREXED FOR INJECTION vs ABSTRAL, answered by our medical review team.
PEMETREXED FOR INJECTION is a Antineoplastic Antifolate that works by Pemetrexed is a folate analog metabolic inhibitor that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent de novo synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEMETREXED FOR INJECTION and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEMETREXED FOR INJECTION is: 500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin 75 mg/m² IV over 2 hours starting 30 minutes after pemetrexed completion. Administer folic acid 350-1000 µg po daily starting 7 days before first dose and continuing until 21 days after last dose, vitamin B12 1000 µg IM 7 days before first dose and every 3 cycles thereafter, and dexamethasone 4 mg po twice daily on day before, day of, and day after pemetrexed.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEMETREXED FOR INJECTION and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEMETREXED FOR INJECTION is classified as Category C. Pemetrexed is teratogenic and embryotoxic in animal studies. In humans, it is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure carries high risk of. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.